Detalimogene voraplasmid (“detalimogene” and previously EG-70) is a unique non-viral gene therapy being studied in the pivotal LEGEND Clinical Trial to treat non-muscle invasive bladder cancer (NMIBC).
At enGene we aim to make genetic medicines mainstream by developing non-viral therapeutics that are delivered directly to mucosal tissues and other organs. Our mission is to deliver innovative non-viral medicines to improve the quality of life for people with urological cancers—starting with non-muscle invasive bladder cancer (NMIBC) and expanding beyond. We are developing innovative solutions with the goal of reducing treatment burden and improving patient outcomes.
Investigational, Non-Viral Gene Therapy for NMIBC
Detalimogene, enGene’s novel, non-viral gene therapy candidate, is under investigation for the treatment of non-muscle invasive bladder cancer (NMIBC)—a complex disease with high patient burden and a growing economic impact on the healthcare system. The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to detalimogene, recognizing its potential to address serious unmet medical needs. These programs provide opportunities for expedited development and review.
Investigational, Non-Viral Gene Therapy for NMIBC
Detalimogene, enGene’s novel, non-viral gene therapy candidate, is under investigation for the treatment of non-muscle invasive bladder cancer (NMIBC)—a complex disease with high patient burden and a growing economic impact on the healthcare system. The U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations to detalimogene, recognizing its potential to address serious unmet medical needs. These programs provide opportunities for expedited development and review.
